| For: | Elsharkawy A, Samir R, El-Kassas M. Fibrosis regression following hepatitis C antiviral therapy. World J Hepatol 2022; 14(6): 1120-1130 [PMID: 35978676 DOI: 10.4254/wjh.v14.i6.1120] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i6/1120.htm |
| Number | Citing Articles |
| 1 |
Jesús García-Bañuelos, Edén Oceguera-Contreras, Ana Sandoval-Rodríguez, Blanca Estela Bastidas-Ramírez, Silvia Lucano-Landeros, Daniela Gordillo-Bastidas, Belinda C. Gómez-Meda, Arturo Santos, Eira Cerda-Reyes, Juan Armendariz-Borunda. AdhMMP8 Vector Administration in Muscle: An Alternate Strategy to Regress Hepatic Fibrosis. Cells 2023; 12(17) doi: 10.3390/cells12172127
|
| 2 |
Dipan Saha, Rudra Paul, Abhijnan Ghosh, Shatavisa Mukherjee. Effectiveness and Safety of Resmetirom in the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Journal of Medical Evidence 2025; 6(4) doi: 10.4103/JME.JME_74_25
|
| 3 |
Laura Huiban, Carol Stanciu, Cristina Maria Muzica, Irina Girleanu, Raluca Avram, Ioana Damian, Robert Nastasa, Ermina Stratina, Sebastian Zenovia, Horia Minea, Remus Stafie, Adrian Rotaru, Ana-Maria Singeap, Stefan Chiriac, Ioana-Miruna Balmus, Anca Trifan. Impact of Treatment with Direct Antivirals on Coagulation Parameters in Patients with Hepatitis C Virus-Related Liver Cirrhosis and Sustained Virological Response. Medicina 2024; 60(9) doi: 10.3390/medicina60091539
|
| 4 |
Azra Bashir, Renuka Arora, Deepti Mehrotra, Manju Bala, Arshed H Parry, Asif Iqball, Shabir A Bhat, Zeeshan A Wani. Non-invasive prediction of significant hepatic fibrosis in individuals with chronic hepatitis C infection using fibrosis risk score and machine learning models. World Journal of Hepatology 2026; 18(3): 117465 doi: 10.4254/wjh.v18.i3.117465
|
| 5 |
Xiao Du, Runyan Niu, Xuexue Liu, Fang Wu, Xian Yang, Xiaolong Ma, Jinping Zhang, Haihui Zhou, Lihua Shao, Siliang Wang. Nanomedicines in the Treatment of Liver Fibrosis: A Review. International Journal of Nanomedicine 2025; doi: 10.2147/IJN.S524078
|
| 6 |
Alexis McCary, Yi-Shin Sheu, Karen Chesbrough, M. Cabell Jonas. Improved Liver Fibrosis Regression After Direct-Acting Antiviral Therapy in Hepatitis C Patients: A Comparison of Patients With and Without MASLD. Clinical Therapeutics 2025; 47(7) doi: 10.1016/j.clinthera.2025.03.011
|
| 7 |
Elisabetta Caon, Roberta Forlano, Benjamin H. Mullish, Pinelopi Manousou, Krista Rombouts. Sinusoidal Cells in Liver Diseases. 2024; doi: 10.1016/B978-0-323-95262-0.00025-5
|
| 8 |
Mohammed El Behery, AhmedI. Elghwab, Ashraf A. Tabll, Elsherbiny H. Elsayed, Mohamed A. Abdelrazek. Serum collagen IV as a predictor for response to direct-acting antivirals hepatitis C therapy. Journal of Immunoassay and Immunochemistry 2024; 45(6) doi: 10.1080/15321819.2024.2415882
|
| 9 |
Alexia Anastasia Stefania Balta, Raisa Eloise Uibariu Barbu, Liliana Baroiu, Valentin Bulza, Florin Bujoreanu, Marius Moroianu, Mariana Daniela Ignat, Simona Claudia Cambrea, Elena Dumea, Valerian Stoian. Evolution of Liver Fibrosis in Romanian HCV Patients Following Treatment with Direct-Acting Antivirals. Journal of Clinical Medicine 2025; 14(22) doi: 10.3390/jcm14228112
|
| 10 |
Oana Koppandi, Bogdan Miutescu, Iulia Ratiu, Alexandru Popa, Camelia Nica, Eyad Gadour, Bogdan Dan Totolici, Raluca Lupusoru, Ana Maria Ghiuchici, Eftimie Miutescu. Longitudinal Changes in Lipid Profile After Sustained Virological Response in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals. Healthcare 2026; 14(4) doi: 10.3390/healthcare14040486
|
| 11 |
Ana-Maria Muñoz-Restrepo, Maria-Cristina Navas, Jimmy Daza, Marcos Girala, Ezequiel Ridruejo, Guido Gerken, Andreas Teufel. Prevention in Hepatology. Journal of Personalized Medicine 2024; 14(2) doi: 10.3390/jpm14020132
|
| 12 |
Tom Ryu, Young Chang, Soung Won Jeong, Jeong-Ju Yoo, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Hong Soo Kim, Seung Up Kim, Jae Young Jang. Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C. Clinical and Molecular Hepatology 2025; 31(2) doi: 10.3350/cmh.2024.0904
|
| 13 |
Zeqi Wu, Jionghua Shi, Siyan Zhou, Wangya Jia, Bin Lu, Mengjuan Wei, Hong Xu, Jian Li, Zhenlin Huang, Lili Ji. Traditional Chinese medicine prescription Mailuoning alleviated liver fibrosis through inhibiting the TGFβ/Smad-mediated extracellular matrix production. Journal of Ethnopharmacology 2026; 358 doi: 10.1016/j.jep.2025.120962
|
| 14 |
Paulina Czarnecka, Kinga Czarnecka, Olga Tronina, Teresa Bączkowska, Aleksandra Wyczałkowska-Tomasik, Magdalena Durlik, Katarzyna Czerwinska. Evaluation of Long-Term Outcomes of Direct Acting Antiviral Agents in Chronic Kidney Disease Subjects: A Single Center Cohort Study. Journal of Clinical Medicine 2023; 12(10) doi: 10.3390/jcm12103513
|
| 15 |
Alejandro Gonzalez-Serna, Anaïs Corma-Gomez, Mercedes Cano, Ricardo Rubio-Sánchez, Carmen Martín-Sierra, Pilar Rincón, Jesica Martín-Carmona, Margarita Pérez, Juan Antonio Pineda, Luis Miguel Real, Juan Macias. Influence of Cellular Aging on Liver Stiffness in Patients With Hepatitis C Virus Achieving Sustained Viral Response. The Journal of Infectious Diseases 2025; 231(5) doi: 10.1093/infdis/jiaf087
|
| 16 |
Nahum Méndez-Sánchez, Mariana M. Ramírez-Mejía, Mariana N. Rincón-Sánchez, Arnulfo E. Morales-Galicia. Direct-Acting Antivirals against Hepatitis C. 2026; doi: 10.1016/B978-0-443-41363-6.00004-4
|
| 17 |
Marta Paula Pereira Coelho, Thais Pontello de Vries, Aline Marcos Pires, Milena Pereira Parreira, Érika Ramos de Alvarenga, Rodrigo Dias Cambraia, Rodrigo Ribeiro dos Santos, Juliana Maria Trindade Bezerra, Enrico Antonio Colosimo, Gifone Aguiar Rocha, Luciana Diniz Silva. Skeletal muscle mass increases after viral eradication with direct‐acting antivirals in patients with chronic hepatitis C: A longitudinal study. Alimentary Pharmacology & Therapeutics 2024; 59(11) doi: 10.1111/apt.17950
|
| 18 |
Simone Kresevic, Mauro Giuffrè, Milos Ajcevic, Lory Saveria Crocè, Agostino Accardo. 9th European Medical and Biological Engineering Conference. IFMBE Proceedings 2024; 113 doi: 10.1007/978-3-031-61628-0_22
|
| 19 |
Mohamed El-Kassas, Wafaa Elakel, Aisha Elsharkawy, Noha Asem, Ahmed Abu-Elfatth, Aya Mostafa, Amr Abdelazeem, Magdy El-Serafy, Mohamed Ibrahem, Eman Alsayed Ghanem, Nermeen Abdeen, Wahid Doss, Gamal Esmat, Doaa Abdeltawab. Comparison of different noninvasive scores for assessing hepatic fibrosis in a cohort of chronic hepatitis C patients. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-79826-w
|
| 20 |
Carlo Smirne, Maria Grazia Crobu, Irene Landi, Nicole Vercellino, Daria Apostolo, David James Pinato, Federica Vincenzi, Rosalba Minisini, Stelvio Tonello, Davide D’Onghia, Antonio Ottobrelli, Silvia Martini, Christian Bracco, Luigi Maria Fenoglio, Mauro Campanini, Alessandro Maria Berton, Alessia Ciancio, Mario Pirisi. Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?. Viruses 2024; 16(12) doi: 10.3390/v16121899
|
| 21 |
Cynthia Lebeaupin, Katelyn L. Donahue, Ken Dower, Thomas A. Wynn, Kevin M. Hart, Thomas Fabre. Unleashing innovative cross-organ fibrosis therapies by harnessing the omics revolution . JCI Insight 2026; 11(13) doi: 10.1172/jci.insight.200155
|
| 22 |
Waleed Attia Hassan, Sherif I. Kamel, Ibrahim Abdel Naby Mahmoud, Nahed Makhlouf, Mahmoud Moubark, Sahar M. Hassany. Assessment of hepatic fibrosis, portal hemodynamic changes, and disease severity in patients with HCV-related liver cirrhosis after sustained virologic response to direct-acting antiviral drugs (DAAs). Egyptian Liver Journal 2023; 13(1) doi: 10.1186/s43066-023-00284-6
|